Compounded Semaglutide vs. Wegovy: What Is the Difference and How Do Costs Compare?

*This article is for informational purposes only and does not constitute medical advice. Speak with a licensed healthcare provider before starting any new medication or treatment program.*

*Pricing data in this article reflects publicly available information as of May 2026. Verify current pricing directly with each provider before making any decision.*

---

If you have searched for "compounded semaglutide vs Wegovy," you have probably found yourself in a tangle of brand names, medical disclaimers, and wildly different price points. Both involve semaglutide as the active ingredient, but they are not the same product, and the difference matters significantly for how you think about safety, cost, and access.

This guide explains what each one is, how they differ, and who might be better served by each option. It does not tell you which to choose. That decision belongs with your healthcare provider.

---

What Is Wegovy?

Wegovy is a brand-name injectable medication manufactured by Novo Nordisk. It contains semaglutide at a maximum dose of 2.4 mg weekly and is specifically FDA-approved for chronic weight management in adults who are obese (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The FDA approved Wegovy in June 2021 after reviewing clinical data from the STEP trial program. In the STEP 1 trial, published in the *New England Journal of Medicine*, participants using semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group [1]. The STEP 5 trial, a two-year study published in *Nature Medicine*, found that sustained weight loss was maintained with continued semaglutide use [2].

Wegovy is a standardized product: every pen is manufactured at Novo Nordisk facilities under FDA oversight, with consistent dosing, sterility testing, and quality controls applied to every batch.

What does Wegovy cost in 2026?

Without insurance or discount programs, Wegovy's retail price typically exceeds $1,000 per month. However, the cash-pay landscape has shifted considerably. Several telehealth platforms now offer Wegovy at significantly lower prices with multi-month commitments: as of May 2026, Ro, WeightWatchers Clinic, and LifeMD have offered Wegovy starting at approximately $249 per month for patients who commit to a 12-month subscription (Ro.com, WeightWatchers.com, LifeMD.com; pricing verified May 2026). The Novo Nordisk savings program (NovoCare) offers $25 per month copays for eligible patients who have commercial insurance but cannot afford their copay.

---

What Is Compounded Semaglutide?

Compounded semaglutide is a prescription medication prepared by a licensed 503A compounding pharmacy using semaglutide as the active pharmaceutical ingredient. It is not manufactured by Novo Nordisk and is not FDA-approved. It is not the same product as Wegovy.

Compounding pharmacies prepare medications for individual patients when commercially available products do not meet a specific patient's needs. Licensed 503A pharmacies operate under state pharmacy board oversight and follow USP standards for sterile compounding. While some 503B outsourcing facilities operate under FDA inspection and current Good Manufacturing Practices, 503A pharmacies are the most common source for patient-specific compounded GLP-1 preparations.

This is the most important compliance distinction in this article: the FDA has issued warning letters to companies that imply or claim equivalence between compounded semaglutide and FDA-approved products like Wegovy. Compounded semaglutide is not the same as Wegovy, it is not a generic version of Wegovy, and it has not been reviewed by the FDA for safety, efficacy, or quality in the way Wegovy has.

Prescriva offers compounded semaglutide starting at $169 per month, which includes the provider consultation, medication, and shipping (Prescriva.com; May 2026).

---

Key Differences at a Glance

*Pricing reflects publicly available information as of May 2026. Verify current rates directly with each provider before making decisions.*

---

Cost Comparison in Depth

The cost question is more nuanced than it first appears, and it has gotten more complicated recently.

Wegovy with insurance

GLP-1 medications for weight management have historically faced significant coverage barriers. Many commercial insurance plans do not cover Wegovy for weight loss, even when a patient has a clinical diagnosis of obesity. Prior authorization requirements add time and administrative friction. Coverage through employer-sponsored plans has tightened as plan sponsors manage GLP-1 costs. Research on GLP-1 medication access has consistently documented high out-of-pocket costs and insurance gaps as primary barriers to treatment [3].

Some plans do cover Wegovy, particularly for patients who also have cardiovascular disease, following the SELECT cardiovascular outcomes trial. If you have commercial insurance, it is worth requesting a benefits review from your plan before assuming coverage is unavailable.

Wegovy savings programs

The NovoCare Patient Assistance Program offers Wegovy at $25 per month for eligible patients with commercial insurance who meet income requirements. For uninsured patients, the NovoCare program may offer free or reduced-cost medication based on income and clinical need (NovoCare.com; accessed May 2026).

The subscription-based cash-pay programs through telehealth platforms (approximately $249/mo at 12-month commitment as of May 2026) represent a meaningful shift. A year ago, the price gap between compounded and brand-name semaglutide was large. It has narrowed, which means cost alone is a less decisive factor than it once was.

Compounded semaglutide cost

Compounded semaglutide programs through telehealth providers typically include the provider consultation, medication, and shipping as part of an all-in monthly price. Prescriva's injectable program starts at $169 per month as of May 2026. Because most insurance plans do not cover compounded medications, the sticker price is the actual price for most patients.

The honest summary: if cost is your primary concern and you can access Wegovy through a savings program or insurer, the math may favor the brand-name product. If you are uninsured or have been denied Wegovy coverage, compounded semaglutide at $169 per month may still offer meaningful cost savings and faster access.

---

*Compounded semaglutide programs typically include the provider consultation, medication, and shipping as part of an all-in monthly price.*

---

Who Might Prefer Wegovy?

Some patients are well-positioned to use Wegovy rather than a compounded alternative.

Patients with insurance coverage. If your plan covers Wegovy and your copay is manageable, the brand-name product offers FDA-reviewed quality assurance and standardized dosing that compounded alternatives cannot match by regulatory definition.

Patients who qualify for savings programs. The NovoCare program and manufacturer discount programs can bring Wegovy costs within range of compounded pricing for eligible patients. If you meet the income and insurance requirements, it is worth applying before defaulting to compounded options.

Patients who prefer FDA-approved medications. There is a meaningful difference in the regulatory backstory of a drug the FDA has reviewed for safety, efficacy, and manufacturing quality versus a compounded preparation that has not undergone that review. For patients who want that institutional assurance, Wegovy is the product that carries it.

Patients with cardiovascular risk. The SELECT trial (published 2023) found that semaglutide 2.4 mg reduced major adverse cardiovascular events in patients with existing cardiovascular disease and obesity, independent of weight loss. This cardiovascular indication is for the FDA-approved branded product. Compounded semaglutide has not been studied in these trials.

---

Who Uses Compounded Semaglutide?

Compounded semaglutide has served a large population of patients who, for various reasons, could not access or afford the brand-name product.

Patients without insurance coverage who cannot afford retail pricing. Even with the narrowing price gap, retail Wegovy at $1,000 or more per month is simply not an option for many people. Compounded programs at $169 per month remain meaningfully more affordable for patients outside the subscription telehealth platform ecosystem.

Patients who have faced coverage denials. Prior authorization processes for Wegovy can take weeks and are frequently denied on first submission. Patients who have gone through the appeals process and still been denied often turn to compounded alternatives as a way to begin treatment without further delay.

Patients in telehealth settings. Compounded semaglutide has become closely associated with the direct-to-consumer telehealth model, where patients can complete an evaluation online and receive medication by mail without navigating a traditional insurance and specialty pharmacy workflow. For patients who value convenience, speed, and a simpler access path, this model fits a genuine need.

Patients who want dose flexibility. Compounding pharmacies can prepare semaglutide at a wider range of doses and titration schedules than are available in the fixed Wegovy pens. Some providers use this flexibility to start patients at lower doses or adjust based on individual tolerance.

---

An Important Caveat on Quality

Not all compounding pharmacies are the same. Quality standards, testing practices, and regulatory compliance vary meaningfully between 503A facilities. A pharmacy that does not test batches for potency or sterility, or that is operating outside its state license in good standing, represents a risk that does not exist with Novo Nordisk's manufacturing process.

If you pursue compounded semaglutide, ask your provider:

• Which pharmacy fills your prescription?
• Is the pharmacy 503A-licensed in your state?
• Does the pharmacy provide certificates of analysis for each batch?
• Is the pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB)?

Prescriva works with licensed 503A compounding pharmacies. That said, pharmacy quality verification is a question every patient should ask, regardless of the telehealth platform they use.

Neither Wegovy nor compounded semaglutide should be started without a licensed healthcare provider evaluating your medical history, current medications, and clinical appropriateness. Both are prescription medications with real contraindications and known side effects. Common side effects associated with semaglutide include nausea, vomiting, diarrhea, and constipation, particularly during the dose-escalation period. Less common but serious risks include pancreatitis, gallbladder disease, and, based on animal studies, a potential risk of thyroid tumors (semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2). Your provider should review the full side effect and contraindication profile with you before starting either medication.

---

Conclusion: The Honest Picture

The price advantage of compounded semaglutide over Wegovy has narrowed as brand-name telehealth pricing has come down. That does not make Wegovy and compounded semaglutide the same product. They are not. Wegovy carries FDA approval and a manufacturing quality assurance process that compounded preparations do not have, by regulatory definition. Compounded semaglutide remains a legally available option through licensed pharmacies and providers, is typically less expensive without insurance, and provides faster access for many patients.

The right choice depends on your insurance situation, your tolerance for regulatory distinction, your budget, and a conversation with a licensed provider who can evaluate your specific health profile.

If you want to understand whether a compounded GLP-1 program is appropriate for you, Prescriva's free eligibility assessment is a starting point.

[Start your free assessment](/quiz)

---

Frequently Asked Questions

Is compounded semaglutide the same as Wegovy? No. Both use semaglutide as the active ingredient, but compounded semaglutide is a different product. It is prepared by a licensed compounding pharmacy, not manufactured by Novo Nordisk, and it is not FDA-approved. The FDA has issued warnings against claims of equivalence between compounded and branded semaglutide products.

Is compounded semaglutide legal? Yes, when prepared by a licensed 503A compounding pharmacy and prescribed by a licensed healthcare provider. The regulatory requirements for compounding have tightened since the FDA resolved the semaglutide shortage in early 2025. Verify that your pharmacy is operating in compliance with current requirements.

Why is compounded semaglutide cheaper than Wegovy? Brand-name pricing reflects research, development, clinical trial costs, and market dynamics specific to the branded pharmaceutical industry. Compounding pharmacies use the active pharmaceutical ingredient and have different cost structures. The price difference does not inherently mean lower quality, but it does make pharmacy accreditation and provider oversight more important, not less.

Does compounded semaglutide work the same way as Wegovy? Compounded semaglutide and Wegovy are not the same product, and they have not been studied in the same clinical trials. The efficacy and safety data from Wegovy's STEP trial program is specific to Novo Nordisk's FDA-approved formulation at established doses. That data cannot be assumed to apply to compounded preparations. Both products use semaglutide as the active ingredient, a GLP-1 receptor agonist that acts on specific receptors to slow gastric emptying and signal fullness, but the regulatory review, manufacturing oversight, and clinical evidence behind Wegovy are distinct from and more extensive than what applies to compounded versions.

Will insurance cover compounded semaglutide? Most commercial insurance plans do not cover compounded medications. Plans that cover GLP-1s typically cover FDA-approved branded products. Prescriva's pricing is designed to be accessible without insurance coverage.

Can I switch from Wegovy to compounded semaglutide? Potentially, but only under your prescribing provider's guidance. Any medication change requires a provider review of your current dose, medical history, and the specific formulation available. Do not change medications without consulting your provider.

---

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." *New England Journal of Medicine*. 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/). DOI: 10.1056/NEJMoa2032183

1. Garvey WT, Batterham RL, Bhatta M, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." *Nature Medicine*. 2022;28(10):2083-2091. [PMID: 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945/). DOI: 10.1038/s41591-022-02026-4

1. Smith BL, Ahmad HA, Erickson AM, et al. "Challenges in the management of obesity." *Journal of Clinical Lipidology*. 2026;20(1):7-17. [PMID: 41708210](https://pubmed.ncbi.nlm.nih.gov/41708210/). DOI: 10.1016/j.jacl.2025.11.015

1. U.S. Food and Drug Administration. "[Compounding and the FDA: Questions and Answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)." FDA.gov. Accessed May 2026.

1. NovoCare by Novo Nordisk. "[Wegovy Savings and Patient Assistance Programs](https://www.novocare.com/obesity/products/wegovy.html)." NovoCare.com. Accessed May 2026.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products including Wegovy (semaglutide injection 2.4 mg).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Prescriva is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.

Pricing Disclaimer: All pricing information is accurate as of May 2026 and is subject to change. Verify current pricing directly with each provider before making any financial or medical decision.